Sort by
Items per page

Send to

Choose Destination

Search results

Items: 24


Pharmacokinetics/pharmacodynamics of lefamulin in a neutropenic murine pneumonia model with Staphylococcus aureus and Streptococcus pneumoniae.

Wicha WW, Strickmann DB, Paukner S.

J Antimicrob Chemother. 2019 Apr 1;74(Supplement_3):iii11-iii18. doi: 10.1093/jac/dkz086.


Efficacy and Safety of IV-to-Oral Lefamulin, a Pleuromutilin Antibiotic, for Treatment of Community-Acquired Bacterial Pneumonia: The Phase 3 LEAP 1 Trial.

File TM Jr, Goldberg L, Das A, Sweeney C, Saviski J, Gelone SP, Seltzer E, Paukner S, Wicha WW, Talbot GH, Gasink LB.

Clin Infect Dis. 2019 Feb 4. doi: 10.1093/cid/ciz090. [Epub ahead of print]


Low Prevalence of Gram-Positive Isolates Showing Elevated Lefamulin MIC Results during the SENTRY Surveillance Program for 2015-2016 and Characterization of Resistance Mechanisms.

Mendes RE, Paukner S, Doyle TB, Gelone SP, Flamm RK, Sader HS.

Antimicrob Agents Chemother. 2019 Mar 27;63(4). pii: e02158-18. doi: 10.1128/AAC.02158-18. Print 2019 Apr.


Antibacterial Activity of Lefamulin against Pathogens Most Commonly Causing Community-Acquired Bacterial Pneumonia: SENTRY Antimicrobial Surveillance Program (2015-2016).

Paukner S, Gelone SP, Arends SJR, Flamm RK, Sader HS.

Antimicrob Agents Chemother. 2019 Mar 27;63(4). pii: e02161-18. doi: 10.1128/AAC.02161-18. Print 2019 Apr.


In Vitro Activity of Lefamulin against Sexually Transmitted Bacterial Pathogens.

Paukner S, Gruss A, Jensen JS.

Antimicrob Agents Chemother. 2018 Apr 26;62(5). pii: e02380-17. doi: 10.1128/AAC.02380-17. Print 2018 May.


In Vitro Activity of the Novel Pleuromutilin Lefamulin (BC-3781) and Effect of Efflux Pump Inactivation on Multidrug-Resistant and Extensively Drug-Resistant Neisseria gonorrhoeae.

Jacobsson S, Paukner S, Golparian D, Jensen JS, Unemo M.

Antimicrob Agents Chemother. 2017 Oct 24;61(11). pii: e01497-17. doi: 10.1128/AAC.01497-17. Print 2017 Nov.


A novel pleuromutilin antibacterial compound, its binding mode and selectivity mechanism.

Eyal Z, Matzov D, Krupkin M, Paukner S, Riedl R, Rozenberg H, Zimmerman E, Bashan A, Yonath A.

Sci Rep. 2016 Dec 13;6:39004. doi: 10.1038/srep39004.


In Vitro Activities of Lefamulin and Other Antimicrobial Agents against Macrolide-Susceptible and Macrolide-Resistant Mycoplasma pneumoniae from the United States, Europe, and China.

Waites KB, Crabb DM, Duffy LB, Jensen JS, Liu Y, Paukner S.

Antimicrob Agents Chemother. 2017 Jan 24;61(2). pii: e02008-16. doi: 10.1128/AAC.02008-16. Print 2017 Feb.


Pleuromutilins: Potent Drugs for Resistant Bugs-Mode of Action and Resistance.

Paukner S, Riedl R.

Cold Spring Harb Perspect Med. 2017 Jan 3;7(1). pii: a027110. doi: 10.1101/cshperspect.a027110. Review.


In Vitro Activity of Lefamulin Tested against Streptococcus pneumoniae with Defined Serotypes, Including Multidrug-Resistant Isolates Causing Lower Respiratory Tract Infections in the United States.

Mendes RE, Farrell DJ, Flamm RK, Talbot GH, Ivezic-Schoenfeld Z, Paukner S, Sader HS.

Antimicrob Agents Chemother. 2016 Jun 20;60(7):4407-11. doi: 10.1128/AAC.00627-16. Print 2016 Jul.


Structural insights into species-specific features of the ribosome from the pathogen Staphylococcus aureus.

Eyal Z, Matzov D, Krupkin M, Wekselman I, Paukner S, Zimmerman E, Rozenberg H, Bashan A, Yonath A.

Proc Natl Acad Sci U S A. 2015 Oct 27;112(43):E5805-14. doi: 10.1073/pnas.1517952112. Epub 2015 Oct 13.


Antimicrobial activity of the pleuromutilin antibiotic BC-3781 against bacterial pathogens isolated in the SENTRY antimicrobial surveillance program in 2010.

Paukner S, Sader HS, Ivezic-Schoenfeld Z, Jones RN.

Antimicrob Agents Chemother. 2013 Sep;57(9):4489-95. doi: 10.1128/AAC.00358-13. Epub 2013 Jul 8.


Disk diffusion and MIC quality control ranges for BC-3205 and BC-3781, two novel pleuromutilin antibiotics.

Ross JE, Sader HS, Ivezic-Schoenfeld Z, Paukner S, Jones RN.

J Clin Microbiol. 2012 Oct;50(10):3361-4. doi: 10.1128/JCM.01294-12. Epub 2012 Jul 18.


Antimicrobial activity of the novel pleuromutilin antibiotic BC-3781 against organisms responsible for community-acquired respiratory tract infections (CARTIs).

Sader HS, Paukner S, Ivezic-Schoenfeld Z, Biedenbach DJ, Schmitz FJ, Jones RN.

J Antimicrob Chemother. 2012 May;67(5):1170-5. doi: 10.1093/jac/dks001. Epub 2012 Jan 27.


Antimicrobial activity of the investigational pleuromutilin compound BC-3781 tested against Gram-positive organisms commonly associated with acute bacterial skin and skin structure infections.

Sader HS, Biedenbach DJ, Paukner S, Ivezic-Schoenfeld Z, Jones RN.

Antimicrob Agents Chemother. 2012 Mar;56(3):1619-23. doi: 10.1128/AAC.05789-11. Epub 2012 Jan 9.


In vitro activity of LK-157, a novel tricyclic carbapenem as broad-spectrum {beta}-lactamase inhibitor.

Paukner S, Hesse L, Prezelj A, Solmajer T, Urleb U.

Antimicrob Agents Chemother. 2009 Feb;53(2):505-11. doi: 10.1128/AAC.00085-08. Epub 2008 Dec 15.


Effective gene transfer to melanoma cells using bacterial ghosts.

Kudela P, Paukner S, Mayr UB, Cholujova D, Kohl G, Schwarczova Z, Bizik J, Sedlak J, Lubitz W.

Cancer Lett. 2008 Apr 8;262(1):54-63. doi: 10.1016/j.canlet.2007.11.031. Epub 2007 Dec 31.


Bacterial ghosts as a novel advanced targeting system for drug and DNA delivery.

Paukner S, Stiedl T, Kudela P, Bizik J, Al Laham F, Lubitz W.

Expert Opin Drug Deliv. 2006 Jan;3(1):11-22. Review.


Bacterial ghosts as novel efficient targeting vehicles for DNA delivery to the human monocyte-derived dendritic cells.

Kudela P, Paukner S, Mayr UB, Cholujova D, Schwarczova Z, Sedlak J, Bizik J, Lubitz W.

J Immunother. 2005 Mar-Apr;28(2):136-43.


DNA-loaded bacterial ghosts efficiently mediate reporter gene transfer and expression in macrophages.

Paukner S, Kudela P, Kohl G, Schlapp T, Friedrichs S, Lubitz W.

Mol Ther. 2005 Feb;11(2):215-23.


Bacterial ghosts are an efficient delivery system for DNA vaccines.

Ebensen T, Paukner S, Link C, Kudela P, de Domenico C, Lubitz W, Guzmán CA.

J Immunol. 2004 Jun 1;172(11):6858-65.


Sealed bacterial ghosts--novel targeting vehicles for advanced drug delivery of water-soluble substances.

Paukner S, Kohl G, Jalava K, Lubitz W.

J Drug Target. 2003 Apr;11(3):151-61.


Sphingomonas pituitosa sp. nov., an exopolysaccharide-producing bacterium that secretes an unusual type of sphingan.

Denner EB, Paukner S, Kämpfer P, Moore ER, Abraham WR, Busse HJ, Wanner G, Lubitz W.

Int J Syst Evol Microbiol. 2001 May;51(Pt 3):827-41.


Supplemental Content

Loading ...
Support Center